The Claim

In adults with type 2 diabetes, once-weekly administration of tirzepatide at doses of 10 mg and 15 mg leads to significant improvements in beta-cell function, as indicated by elevated HOMA2-B indices and reduced proinsulin/insulin and proinsulin/C-peptide ratios, when compared to treatment with dulaglutide or placebo.

Source: Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
72score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

In people with type 2 diabetes, a weekly injection of tirzepatide at 10 mg or 15 mg is associated with better function of insulin-producing cells in the pancreas, shown by specific biomarker changes, compared to other treatments like dulaglutide or no active treatment.

See the scientific wording

In adults with type 2 diabetes, once-weekly tirzepatide at doses of 10 mg and 15 mg significantly improves beta-cell function, as measured by increased HOMA2-B indices and reduced proinsulin/insulin and proinsulin/C-peptide ratios, compared to dulaglutide or placebo, suggesting enhanced insulin processing and reduced pancreatic stress.

Why this might work

Tirzepatide binds to two specific receptors on insulin-producing cells in the pancreas, which helps these cells work more efficiently under high sugar conditions. This reduces a type of cellular strain that normally causes the cells to release immature insulin parts. As a result, more fully formed insulin is made and released, and fewer faulty parts leak out, which means the pancreas is under less stress and works better.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

    This study found that a weekly shot called tirzepatide helps the pancreas make insulin better and with less strain, compared to other similar drugs. It shows the pancreas is releasing fewer faulty insulin parts, meaning it’s working more efficiently.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.